REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.
The Pharma Letter6h
FDA accepts Replimune’s melanoma candidate for priority review
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...
RS-NEWS10h
How Skin Cancer Treatments Are Being Transformed for Better Outcomes
The future of skin cancer treatment looks even more promising. Advances in artificial intelligence (AI) are revolutionizing ...
ImmunityBio: Despite Anktiva's Clinical Promise, This Remains A Difficult Investment
ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.
Consultations For Cancer And ADHD Medicines Close Soon
Pharmac is also consulting on a joint proposal with Medsafe to increase access to ADHD medicines. The consultation is considering changes to the regulations and funding restrictions stimulant ...